The ISPOR mission is to translate pharmacoeconomics and outcomes research into practice. We encourage health care practitioners, health care purchasers, and health care decision-makers, as well as pharmacoeconomic and outcomes researchers to attend this meeting.	In this program, SPECIAL TRACKS are identified for the following:
		Health care practitioner (physician, pharmacist, nurse, other health care professionals)
		Health care decision-maker & purchaser (health plans, insurance companies, government)
		Outcomes (quality-of-life) researchers
		Pharmacoeconomic (health economic) researchers
	Choose your TRACK and follow the symbol in the program to help you select presentations that match your interest.

ECONOMICS & OUTCOMES ISSUES IN CARDIOVASCULAR DISEASE
	PCVD1	A COMPARISON OF THE EMEA AND FDA DRAFT GUIDELINES IN CONGESTIVE HEART FAILURE (CHF) WITH PARTICULAR REFERENCE TO QUALITY OF LIFE (QOL) OUTCOMES Wiklund I1, Apolone G2, Acquadro C3, Chassany O4, Jambon B3, Fullerton S1 for the European Regulatory Issues on QoL Assessment (ERIQA) group; 1Astra Haessle, Moelndal, Sweden; 2Mario Negri Institute, Milano, Italy; 3Mapi Research Institute, Lyon, France; 4Höpital Lariboisiére, Paris, France
	PCVD2	HYPERTENSION DISEASE MANAGEMENT: A RANDOMIZED, COMPARATIVE TRIAL Borenstein J1, Saltiel M1, Graber G1, Ryu S1, Jackson A1, Weingarten S1, 1Cedars-Sinai Health System; Los Angeles, CA, USA
	PCVD3	COST EFFECTIVENESS OF THROMBOLYTIC AGENTS IN THE TREATMENT OF ACUTE MYOCARDIAL INFARCTION Kamath T, Liu G, Chang K, Cherian J, Feier C, Kerrigan P, Law T, Patel A, Patel D, Patel R, Thompson J, University of Southern California, Los Angeles, CA, USA
	PCVD4	AN ECONOMIC MODEL OF HYPERTENSION IN ONTARIO Bentkover JD1, Stewart EJ1, Magar R2, Saffar J-M3, Greene EM4, Klawansky S5, Parison D6, 1Innovative Health Solutions (IHS), Brookline, MA, USA; 2Health Economics Research, Secaucus, NJ, USA; 3A.T. Kearney, Boston, MA, USA; 4KPMG LLP, Dublin, Ireland; 5Consultant to IHS, Boston, MA, USA; 6Formerly Novartis Pharmaceuticals Corporation, Montreal, Quebec, Canada
	PCVD5	DELPHI PANEL SURVEY ON CURRENT HYPERTENSION TREATMENT PATTERNS Richter A1, Dombeck MP1, Ostrowski C2, 1Research Triangle Institute, Research Triangle Park, NC, USA; 2Clinical consultant, Durham, NC, USA
	PCVD7	IDENTIFICATION OF COMOROBIDITIES AMONG A HYPERTENSIVE POPULATION USING ADMINISTRITATIVE CLAIMS AND MEDICAL RECORDS DATA Connors H, Cleary M, Clouse J, Ingenix, Minneapolis, MN, USA
	PCVD8	SELECTIVE USE OF CALCIUM ANTAGONISTS FOR HIGH RISK HYPERTENSIVES Leader S, Pracon, Reston, VA, USA, Roht L, Hoechst Marion Roussel, Kansas City, MO, USA
	PCVD9	LEFT VENTRICULAR SYSTOLIC FUNCTION AND DRUG UTILIZATION AMONG HOSPITALIZED PATIENTS WITH CONGESTIVE HEART FAILURE Wang AY1, Schiff GD2, Stamos TD3, Weiss KB3, Thomas J1, 1Pharmacy School, Purdue University, W. Lafayette, IN, USA; 2The Cook County Hospital, Chicago, IL, USA; 3Rush-Presbyterian-St.Luke's Medical Center, Chicago, IL, USA
	PCVD10	ATTAINMENT OF LIPID GOALS IN PATIENTS TREATED WITH HMG-COA REDUCTASE INHIBITORS: A RETROSPECTIVE STUDY Nichol MB1, Jones J1, David A, Godolphin DA2, Bernstein E2, 1University of Southern California, Los Angeles, CA, USA; 2Equinox Group, Lexington, MA, USA
	PCVD11	FORMULARY ANALYSIS OF ANGIOTENSIN II ANTAGONISTS IN A UK TEACHING HOSPITAL Wheeldon N, Moore A P, Jennings M, Northern General Hospital, Sheffield, England
	PCVD12	EFFECTS OF AN EDUCATIONAL CAMPAIGN ON MEDICATION USE FOR CORONARY ARTERY DISEASE (CAD) Perry CF1, Talbert RL2, 1Walgreens Health Initiatives, Deerfield, IL, USA; 2University of Texas at Austin and UTHSC, San Antonio, TX, USA
	PCVD13	ASSESSING LIPID-LOWERING INTERVENTIONS IN MANAGED CARE SETTINGS Felber G1, Jones K2, Perez E1, Patel B1, 1Total Therapeutic Management, Inc, Atlanta, GA, USA; 2Principal Health Care Plans of Jacksonville, Jacksonville, FL, USA
	PCVD14	USE OF CONFIDENCE INTERVALS TO ESTIMATE THE COST-EFFECTIVENESS OF ABCIXIMAB Reed SO1, Mullins CD2, Magder LS3, 1University of Washington School of Pharmacy, Seattle, WA, USA; 2University of Maryland School of Pharmacy, Baltimore, MD, USA; 3University of Maryland School of Medicine, Baltimore, MD, USA
	PCVD15	A UK PRIMARY CARE DATABASE (UKPCD)-UK MEDIPLUS IS A READILY AVAILABLE RESEARCH TOOL FOR DETERMINING THE PREVALENCE OF PATIENTS WITH A HISTORY OF OBESITY OR OVERWEIGHT, THEIR TREATMENT, AND ASSOCIATED CO-MORBIDITIES Starling A, Gaskin M, Harrison P, Thorington N, Disease Treatment and Outcomes Group, IMS HEALTH, Middlesex, England
	PCVD16	THE ECONOMIC AND HEALTH BENEFITS OF CONVERSION TO NORMAL SINUS RHYTHM Caro JJ, Migliaccio, Walle K, Klittich WS, O'Brien JA, Caro Research, Concord, MA, USA
ECONOMICS & OUTCOMES ISSUES OF PSYCHOLOGICAL/NEUROLOGICAL DISORDERS
	PNP1	DEVELOPMENT AND INITIAL VALIDATION OF A BRIEF MENTAL HEALTH OUTCOME MEASURE Lenderking WR1,2, Blais MA2, Leahy L2, Baer L2, 1Abt Associates Clinical Trials, Cambridge, MA, USA; 2Massachusetts General Hospital, Boston, MA, USA
	PNP2	IMPACT OF CLINICIAN EDUCATION ON LONG-TERM ANTIDEPRESSANT PRESCRIBING Fulop G, Robinson Jr D, Hirsch L, Hensleigh M, Maldonato D, Brookler R, Carides P, Kelly M, Merck-Medco Managed Care L.L.C., Montvale, NJ, USA
	PNP3	RACIAL AND GENDER DIFFERENCES IN ACCESS TO A NEW DRUG THERAPY Pinto LA1, Schulz RM1, Young V1, Jordan J2, 1University of South Carolina, Columbia, SC, USA; 2Glaxo Wellcome Inc., Research Triangle Park, NC, USA
	PNP4	ECONOMIC OUTCOMES OF ANTIDEPRESSANT USE IN A MANAGED CARE ORGANIZATION White TJ1, Nichol MB2, 1Prescription Solutions - A subsidiary of PacifiCare Health Systems, Costa Mesa, CA, USA; 2University of Southern California School of Pharmacy, Los Angeles, CA, USA
	PNP5	PHARMACOECONOMIC ANALYSIS OF PATTERNS OF ANTIDEPRESSANT USE Egan T, Baran R, McGhan W, University of the Sciences in Philadelphia, Philadelphia, PA, USA
	PNP6	COST-BENEFIT ANALYSIS OF ORAL ANTIDEPRESSANTS IN THE MANAGEMENT OF MAJOR DEPRESSIVE DISORDER - A MANAGED CARE PERSPECTIVE Chen P, University of North Carolina, Chapel Hill, NC, USA
	PNP7	SELECTIVE SERATONIN REUPTAKE INHIBITOR (SSRI) UTILIZATION PATTERNS IN PATIENTS WITH OR WITHOUT A DEPRESSION DIAGNOSIS Brondum J1, Klein EG2, Clouse JC1, Meyer JW1, 1Ingenix, Eden Prairie, MN, USA; 2Eli Lilly and Co., Indianapolis, IN, USA
	PNP8	DEPRESSION IN POOR, YOUNG WOMEN: FLUXETINE VS. SERTRALINE Singer ME1, 1Case Western Reserve University at Metro Health Medical Center, Cleveland, OH, USA
	PNP9	ANTIDEPRESSANT IMPACT ON SOCIAL FUNCTIONING: REBOXETINE VERSUS FLUOXETINE Venditti LN1, Arcelus A1, Birnbaum H1, Greenberg P1, Barr CE2, Rowland C2, Williamson T2, 1Analysis Group/Economics, Cambridge, MA, USA; 2Pharmacia & Upjohn, Kalamazoo, MI, USA
	PNP10	COST-BENEFIT ANALYSIS OF FLUOXETINE INCLUSION IN THE MEDI-CAL FORMULARY Field J, Juzba M, University of Southern California School of Pharmacy, Department of Pharmaceutical Economics and Policy, Los Angeles, CA, USA
	PNP11	DIABETES MELLITUS AND OTHER CARDIOVASCULAR RISK FACTORS IN PATIENTS RECEIVING ANTIDEPRESSANT DRUGS Taylor AT1, Athar MM1, Wagner PJ2, Ahmed A2, 1University of Georgia College of Pharmacy; 2Medical College of Georgia School of Medicine, Athens and Augusta, GA, USA
	PNP12	DIRECT MEDICAL COST DIFFERENCES BETWEEN ALZHEIMER'S PATIENTS AND ELDERLY NON-ALZHEIMER'S PATIENTS IN A MANAGED CARE ORGANIZATION Richards KM1, Shepherd MD1, Snyder EH2, 1The University of Texas at Austin, TX, USA; 2Novartis Pharmaceuticals, East Hanover, NJ, USA
	PNP13	DEVELOPMENT OF A COST CONSEQUENCES COMPUTER SIMULATION MODEL OF BIPOLAR DISORDER Mather DB1, Bell E2, Bryant-Comstock L1, Sullivan SD2, Keck PE Jr3, 1Glaxo Wellcome Inc., Research Triangle Park, NC, USA; 2University of Washington, Seattle, WA, USA; 3University of Cincinnati, Cincinnati, OH, USA
	PNP14	COST AND UTILIZATION OUTCOMES OF PATIENTS TREATED FOR SCHIZOPHRENIA IN A MEDICAID POPULATION Christensen D1, Wingerson D2, Stergachis A3, Durkin M4, 1University of North Carolina School of Pharmacy, CHapel Hill, NC, USA; 2Harborview Medical Center, Seattle, WA, USA; 3University of Washington School of Pharmacy, Seattle, WA, USA; 4 Janssen Research Foundation, Titusville, NJ, USA
	PNP15	RETROSPECTIVE DATABASE ANALYSIS: ADJUSTMENTS REQUIRED FOR ANTIPSYCHOTIC DOSING AND DURATION PATTERNS Booth G1, Hutchins D1, Signa W1, Johnstone B2, Tunis S2, Mitrany D1, 1PCS Health Systems Inc., Scottsdale, AZ, USA; 2Eli Lilly and Company, Indianapolis, IN, USA
	PNP16	ANTIPSYCHOTIC DRUG USE PATTERNS AND THE COST OF TREATING SCHIZOPHRENIA OVER A TWO YEAR PERIOD McCombs JS, Luo M, and Shi L, University of Southern California, Los Angeles, CA, USA
	PNP17	ECONOMIC BURDEN DUE TO COSTS OF PSYCHOTROPIC MEDICATIONS FOR THE MANAGEMENT OF PSYCHIATRIC DISORDERS IN INDIA Chaturvedi SK, National Institute of Mental Health & Neurosciences, Bangalore, India
	PNP18	USE OF ANTIPSYCHOTIC MEDICATIONS AT BASELINE IN A PROSPECTIVE STUDY OF THE COURSE OF TREATMENT FOR SCHIZOPHRENIA Johnstone BM1, Mukundan MV1,2, Loosbrock DL1, Dulisse BK1,3, 1Health Outcomes Evaluation Group, United States Medical Division, Eli Lilly and Company, Indianapolis, IN, USA; 2Department of Economics, Indiana University at Indianapolis, Indianapolis, IN, USA; 3Statistical and Mathematical Sciences, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
	PNP19	PSYCHOTROPIC PRESCRIBING FOR THE ELDERLY IN AMBULATORY CLINICS Aparasu RR, Mort JR, College of Pharmacy, South Dakota State University, Brookings, SD, USA
	PNP20	ANTIPSYCHOTIC UTILIZATION RATIOS: DIFFERENCES AMONG AGE, GENDER, AND PAYER COMBINATIONS Hutchins D1, Johnstone B2, Tunis S2, Gevirtz F, Li Z1, Mitrany D1, 1PCS Health Systems Inc., Scottsdale, AZ, USA; 2Eli Lilly and Company, Indianapolis, IN, USA
	PNP21	THE ECONOMIC COSTS OF HEROIN ADDICTION Mark T, Juday TR, The MEDSTAT Group, Washington, DC, USA
	PNP22	HYPNOTIC DRUGS CONSUMPTION IN RUSSIA Gorkov V, Kobina S, Chapurin Y, Churilin S, Center of Mental Health, Moscow, Russia
	PNP23	THE IMPACT OF ALCOHOL CONSUMPTION AND SMOKING ON SHORT-TERM HEALTH CARE COSTS IN A MANAGED CARE POPULATION Field J, McCombs J, Sengupta N, University of Southern California School of Pharmacy, Department of Pharmaceutical Economics and Policy, Los Angeles, CA, USA
ECONOMICS & OUTCOMES ISSUES OF RESPIRATORY DISEASE
	PRD1	BARRIERS TO EFFECTIVE ASTHMA DISEASE MANAGEMENT: LIMITATIONS IN PHYSICIAN KNOWLEDGE OF TREATMENT GUIDELINES Ricci J1, Stewart W1, Murphy S2, 1Innovative Medical Research, Inc., Baltimore, MD, USA; 2Glaxo Wellcome Inc., Research Triangle Park, NC, USA
	PRD2	A TELEPHONE-BASED APPROACH FOR MONITORING HEALTH STATUS IN ASTHMA DISEASE MANAGEMENT Ricci J1, Stewart W1, Chee E1, Murphy S2, 1Innovative Medical Research, Inc., Baltimore, MD, USA; 2Glaxo Wellcome, Inc., Research Triangle Park, NC, USA
	PRD3	DEVELOPMENT OF AN ASTHMA QUALITY-OF-LIFE QUESTIONNAIRE FOR NATIVE AMERICAN ADULTS (AQLQ-NAA) Gupchup GV1, Teel M1, Singhal PK1, Tonrey L2, Riley K2, Hubbard JH1, 1University of New Mexico, College of Pharmacy, Albuquerque, NM, USA; 2Albuquerque PHS Indian Hospital, Albuquerque, NM, USA
	PRD4	COST BENEFIT ANALYSIS OF ASTHMA EDUCATION PROGRAMS Liu G, Kamath T, Huang A, Grewal A, Trinh H, Hong S, Kim J, Yu L, Gu P, Hariri N, Sadighim R, University of Southern California, Los Angeles, CA, USA
	PRD5	THE FIRST PHARMACO-ECONOMICS STUDY IN ASTHMA - SOME IMPORTANT OBSERVATIONS Andersson F1, 1Astra Draco AB, Lund, Sweden
	PRD7	THE USE OF GENERALIZED ESTIMATING EQUATIONS IN LONGITUDINAL STUDIES OF RESOURCE UTILIZATION: THE CASE OF ASTHMA Itzler RF1, Dasbach EJ1, Koch GG2, Heyse JF1, 1Merck Research Laboratories, Blue Bell, PA, USA; 2University of North Carolina, Chapel Hill, NC, USA
	PRD8	A RETROSPECTIVE DATABASE STUDY OF PATIENT ADHERANCE WITH ASTHMA TREATMENT REGIMENS Hutchison S, Beno C, PCS Health Systems, Inc., Outcomes Research Department, Scottsdale, Arizona, USA
	PRD9	THE HEALTHCARE UTILIZATION OF PATIENTS WITH CHRONIC SINUSITIS Edelman-Lewis B1, Lydick E2, Emani S1, Bentkover S1, 1Fallon Clinic, Worcester, MA, USA; 2SmithKline Beecham Pharmaceuticals, Collegeville, PA, USA
	PRD10	COST-EFFECTIVENESS OF AZITHROMYCIN AND CO-AMOXICLAV IN ACUTE SINUSITIS Karpov O, Zaytsev A, Institute of Pharmacology, Saint-Petersburg, Russia
	PRD11	QUALITY OF LIFE ASSESSMENT IN ALLERGIC RHINITIS PATIENTS TREATED WITH LORATADINE Hauser R, Smeeding J, Koeller J, University of Texas Center for Pharmacoeconomics, Austin, TX, USA
	PRD12	DETERMINING THE CLINICAL RELEVANCE OF STATISTICALLY SIGNIFICANT IMPROVEMENTS IN QUALITY OF LIFE Schleusener D, Coen M, Thompson A, Hoechst Marion Roussel, Kansas City, MO, USA
	PRD13	DEVELOPMENT OF A NASAL COMFORT INDEX FOR NASAL SPRAYS IN ADULTS WITH SEASONAL ALLERGIC RHINITIS Keresteci MA1, Ungar W1, Ryan N1, Mendelson L2, Tarlo S3, Nadal JC4, Rosano ME4, Evans C4, 1Innovus Research Inc, Burlington, Ontario, Canada; 2Connecticut Asthma and Allergy, West Hartford, CT, USA; 3University of Toronto, Toronto, Ontario, Canada; 4Astra U.S. Inc. Pharmaceuticals., Westborough, MA, USA
	PRD14	A PHARMACOECONOMIC EVALUATION OF BUDESONIDE AQUEOUS NASAL SPRAY AND FLUTICASONE PROPIONATE NASAL SPRAY IN THE TREATMENT OF PERENNIAL ALLERGIC RHINITIS Stáhl E, Wang E, Van Rompay W, Thomson D, Astra Draco AB, Lund, Sweden, Astra Pharma Inc., Mississaugp, Ontario, Canada, HEDM, Mechelen, Belgium, Montreal General Hospital, Montreal, Mc Gill University, Quebec, Canada
ECONOMICS & OUTCOMES ISSUES OF INFECTIOUS DISEASE
	PID1	COST-EFFECTIVENESS ANALYSIS OF RECOMBINANT HUMAN ERYTHROPOIETIN VS. TRANSFUSION IN HIV PATIENTS TREATED WITH ZIDOVUDINE Juzba M, Hay J, University of Southern California School of Pharmacy, Department of Pharmaceutical Economics and Policy, Los Angeles, CA, USA
	PID2	INCREASING COST OF MANAGING AIDS IN THE LAST YEAR OF LIFE O'Brien JA, Pierce D, Jackson-Kelley H, Cutter T, Caro JJ, Car Research, Concord, MA, USA
	PID3	ECONOMIC EVALUATION OF SYSTEMIC TREATMENTS FOR CMV RETINITIS IN PERSONS WITH AIDS IN SWITZERLAND Lee TA1, Sullivan SD1, Ramsey SD1, Steger P2, Williamson T2, Pliel A2, 1University of Washington, Seattle, WA, USA; 2Pharmacia and UpJohn, Kalamazoo, MI, USA
	PID4	A RETROSPECTIVE DATABASE STUDY OF AIDS INITIAL TREATMENT REGIMENS, SWITCHING PATTERNS, AND PATIENT ADHERANCE Hutchison S, Beno C, PCS Health Systems, Inc., Outcomes Research Department, Scottsdale, Arizona, USA
	PID5	DEVELOPMENT AND INITIAL ASSESSMENT OF THE PATIENT MEDICATION ADHERENCE QUESTIONNAIRE-7-7 (PMAQ7) FOR USE IN INTERNATIONAL HIV STUDIES Metcalf MA1, Jhingran P1, Tolson JM1, Arpinelli F2, Pham S1, 1Glaxo Wellcome Inc., Research Triangle Park, NC, USA; 2Glaxo Wellcome S.p.A., Verona, Italy
	PID6	HEALTH-RELATED QUALITY OF LIFE CHANGES IN PATIENTS WITH ONYCHOMYCOSIS Lubeck DP1, Doyle JJ2, Schein JR2, Potter LP3, Prebil LA3, 1University of California/San Francisco, San Francisco, CA, USA; 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; 3Lewin-TAG, San Francisco, CA, USA
	PID7	COST-EFFECTIVE ANALYSIS OF ORAL ONYCHOMYCOSIS THERAPIES USING IDAHO MEDICAID CLAIMS DATA Alemao EA, Cady PS, Phatak HM, Culbertson VL, College of Pharmacy, Idaho State University, Pocatello, ID, USA
	PID8	TREATMENT OF ONYCHOMYCOSIS OF THE NAIL IN A MEDICAID POPULATION Phatak HM, Cady PS, Alemao EA, Culbertson VL, College of Pharmacy, Idaho State University, Pocatello, ID, USA
	PID9	EVALUATION OF THE OUTCOMES OF PATIENTS ON HEMODIALYSIS RECEIVING AMPHOTERICIN B LIPID COMPLEX (ABLC) Coley KC, Zak MB, Branch RA, University of Pittsburgh, Pittsburgh, PA, USA
	PID10	DEVELOPMENT AND VALIDATION OF A DECISION ANALYTIC FRAMEWORK (DAF) TO EVALUATE THE ECONOMIC IMPACT OF SUSPECTED MENINGITIS (SM) Parasuraman TV1, Deverka PA2, Toscani MR1, on behalf of the Meningitis Consensus Panel*; 1Hastings Healthcare Group, Inc., Pennington, NJ, USA; 2Merck-Medco Managed Care, Montvale, NJ, USA * Modlin J, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA; Reiss M, Medical Neurology Associates, Hinsdale, IL, USA, and Loyola University School of Medicine, Maywood, IL, USA; Romero J, University of Nebraska College of Medicine and Creighton University School of Medicine, Omaha, NE, USA; Rotbart H, University of Colorado, Denver, CO, USA; Sawyer MH, University of California, San Diego, CA, USA; Sealy D, Montgomery Center for Family Medicine, Greenwood, SC, USA; Silverman R, Long Island Jewish Medical Center, New Hyde Park, NY, USA
	PID11	COST EFFECTIVENESS OF FIVE ORAL ANTIMICROBIALS FOR ACUTE OTITIS MEDIA Kaplan-Machlis B1, Wandstrat TL2, Beane JS1, 1West Virginia University, School of Pharmacy, Charleston, WV, USA, 2Novartis Pharmaceuticals, Inc., East Hanover, NJ, USA
	PID12	THE RATE OF INFECTIONS CONCURRENT WITH INTRAVENOUS PATIENT CONTROLLED ANALGESIA Shmuely Y, Lydick E, SmithKline Beecham, Philadelphia, PA, USA
	PID13	LONG-TERM EFFICACY OF LOCAL GUIDELINES TO IMPROVE ANTITETANUS PROPHYLAXIS AND REDUCE COSTS IN AN EMERGENCY DEPARTMENT Elkharrat D, Chevret S, Le Corre A, Benhamou F, Emergency Department. Hopital Lariboisi&3228;re, Paris, France
	PID14	ECONOMIC ANALYSIS OF ANTIMICROBIAL AGENTS FOR HOSPITAL-ACQUIRED PNEUMONIA Wong AH, Oh PI, Shear NH, HOPE Research Centre, Sunnybrook & Women's College Health Science Centre, Toronto, Ontario, Canada
	PID15	INFLUENCE OF MOTIVATING FACTORS AND BARRIERS ON INFLUENZA VACCINATION IN AN EMPLOYED POPULATION Parasuraman TV1, Patterson R1, Toscani MR1, Coleman MJ2, Pizzi LT1, 1Hastings Healthcare Group, Inc., Pennington, NJ, USA; 2Wyeth-Ayerst Pharmaceuticals, St. Davids, PA, USA
	PID16	ECONOMIC STUDY OF CEPHALOSPORINS IN THE TREATMENT OF MODERATE LOWER RESPIRATORY TRACT INFECTION Zhigao HE, Jie CHEN, Department of Hospital Management, Shanghai Medical University, Shanghai, China
	PID17	DETERMINATION OF THE COST-EFFECTIVENESS OF A TUBERCULOSIS PREVENTION PROGRAM ALONG THE U.S. / MEXICO BORDER USING MARKOV PROCESS MODELING WITHIN A PREVENTION EFFECTIVENESS FRAMEWORK Borrego ME1, Draugalis JR2, Slack MK2, Cox, ER2, 1University of New Mexico College of Pharmacy, Albuquerque, NM, USA ; 2The University of Arizona College of Pharmacy, Tucson, AZ, USA
	PID18	THE COST OF INFLUENZA IN THE EMERGENCY ROOM AND HOSPITAL Cox FM1, Okamoto LJ2, Cobb MM1, Chua WQ1, 1Glaxo Wellcome, Research Triangle Park, NC, USA; 2NDC Health Information Services, Phoenix, AZ, USA
	PID19	COST-EFFECTIVENESS OF ONCE-DAILY CLARITHROMYCIN COMPARED TO AMOXYCILLIN/CLAVULANIC ACID IN THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS Hutton J1, Ryan J2, Conway D2, 1MEDTAP International, London, UK, 2Abbott Laboratories, Abbott Park, IL, USA
	PID20	SAVINGS IN DIRECT MEDICAL COSTS PRODUCED BY AN INHALED SOLUTION OF TOBRAMYCIN (TOBI) IN CHILDREN WITH CYSTIC FIBROSIS LeLorier J1, Perreault S1, Birnbaum H2 and Greenberg P2, 1Centre de recherche, Centre hospitalier de l'Université de Montréal, Campus Hötel-Dieu, Montréal, Canada; 2Analysis Group, Boston, MA, USA
ECONOMICS & OUTCOMES ISSUES OF ARTHRITIC DISEASE
	PAD1	EFFICACY OF AN INTERVENTION TO RATIONALIZE PRESCRIBING OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) Elkharrat D, Chastang C, Le Corre A, Caulin C, Emergency Department, Hopital Lariboisiäre, Paris, France
	PAD2	OPTIMIZATION OF A HMO's NSAID PORTFOLIO FOLLOWING THE INTRODUCTION OF CELECOXIB Pettitt AD1, Goldstein JL2, McElwee N1, Pena B1, 1Pfizer Inc. New York, NY, USA; 2University of Illinois-Chicago, Chicago, IL, USA
	PAD3	RESPONSIVENESS OF WOMAC IMPROVEMENT TO PATIENTS' AND PHYSICIANS' GLOBAL ASSESSMENT (PtGA & PhGA) OF IMPROVEMENT AMONG OSTEOARTHRITIS PATIENTS (OA) Zhao SZ, Arguelles L, Burke TA, & Osterhaus JT, G.D. Searle & Co., Skokie, IL, USA
	PAD4	CLINICALLY-MEANINGFUL IMPROVEMENT OF HEALTH-RELATED QUALITY OF LIFE (HRQOL) AMONG OSTEOARTHRITIS (OA) PATIENTS Zhao SZ, Arguelles L, Burke TA, & Osterhaus JT, G.D. Searle & Co., Skokie, IL, USA
	PAD5	RETROSPECTIVE EVALUATION OF CONCOMITANT GASTROINTESTINAL DRUG USE WITH NSAID THERAPY AMONG PATIENTS WITH ARTHRITIS Lapane K1, Pettitt D2, Dooley J2, Spooner J1; 1Brown University, Providence, RI, USA; 2Outcomes Research, Pfizer Inc., New York, NY, USA
	PAD6	ASSESSMENT OF THE ECONOMIC AND HUMANISTIC OUTCOMES OF THE WEST VIRGINIA MEDICAID'S PRIOR AUTHORIZATION POLICY FOR NSAIDS Momani A, Madhavan SS, Small S, West Virginia University School of Pharmacy, Morgantown, WV, USA
	PAD7	PHARMACOEPIDEMIOLOGY OF INITIAL DISEASE MODIFYING ANTIRHEUMATIC DRUG (DMARD) THERAPY IN A MANAGED CARE ORGANIZATION (MCO) Griffiths RI1, Bar-Din M1, Yelin E2, Herbert RJ1, Sullivan EM1, Slurzberg JEF3, MacLean C4, 1Covance, Washington, DC, USA; 2University of California at San Francisco, San Francisco, CA, USA; 3Cypress Bioscience, Inc., San Diego, CA, USA; 4University of California at Los Angeles, Los Angeles, CA, USA
	PAD8	INTERPRETATION OF HAQ DISABILITY INDEX IMPROVEMENT AMONG RHEMATOID ARTHRITIS (RA) PATIENTS IN RANDOMIZED CLINICAL TRIALS Zhao SZ, Arguelles L, Burke TA, & Osterhaus JT, G.D. Searle & Co., Skokie, IL, USA
ECONOMICS & OUTCOMES ISSUES OF CANCER
	PCD1	DIRECT AND INDIRECT COSTS OF CHEMOTHERAPY-INDUCED TOXICITY Calhoun E, Fishman D, Roland P, Lurain J, Bennett C, Northwestern University, Chicago, IL, USA
	PCD2	COSTS ASSOCIATED WITH CHEMOTHERAPY-INDUCED TOXICITIES: A REVIEW OF THE LITERATURE Jackson S1, Peeples P1, Hanson-Divers C2, 1Alza Corporation, Palo Alto, CA, USA; 2Center for Health Information, Chesapeake, VA, USA
	PCD3	COSTS AND OUTCOMES OF HOME VERSUS HOSPITAL-BASED TREATMENT OF FEBRILE NEUTROPENIA IN PEDIATRIC ONCOLOGY PATIENTS Raisch DW1,2, Holdsworth MT2, Winter SS2, Hutter JJ3, Graham ML3, 1VA Cooperative Studies Program Clinical Research Pharmacy, Albuquerque, NM, USA; 2University of New Mexico, Albuquerque, NM, USA; 3University of Arizona, Tuscon, AZ, USA
	PCD4	THE VALUE OF HOME CARE IN METASTATIC BREAST CANCER MANAGEMENT: MODELING ORAL VERSUS INTRAVENOUS CHEMOTHERAPY AT HOME AND AT AN OUTPATIENT CLINIC Mathes A, Hay J, University of Southern California, Los Angeles, CA, USA
	PCD5	RELIABILITY AND VALIDITY OF THE BREAST EVALUATION QUESTIONNAIRE (BEQ): AN OUTCOME MEASURE FOR BREAST IMPLANT STUDIES Lenderking WR1, Tafesse E1, 1Abt Associates Clinical Trials, Cambridge, MA, USA
	PCD6	COMPARISON OF THE MCMASTER'S HEALTH UTILITIES INDEX-MARK III AND THE EUROQOL-5D IN A SURGICAL BREAST CANCER POPULATION Namjoshi MA, Taylor TN, Hohl RJ, University of Iowa, Iowa City, IA, USA
	PCD7	INITIAL, MAINTENANCE, AND TERMINAL CARE costS OF BREAST CANCER TREATMENT Noe LL1, Vreeland MG1, Gore MG2, Trotter JP1, 1Ovation Research Group, Highland Park, IL, USA; 2Zeneca Pharmaceuticals, Wilmington, DE, USA
	PCD8	AN ANALYSIS OF RESEARCH AND POLICY-RELEVANT CHARACTERISTICS OF QUALITY OF LIFE ASSESSMENTS IN PROSTATE CANCER Sommers SD1, Ramsey SD2, 1Department of Pharmacy, University of Washington, Seattle, WA, USA; 2Department of Medicine, University of Washington, Seattle, WA, USA
	PCD9	UTILIZATION OF COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM) TREATMENTS AMONG PROSTTAE CANCER PATIENTS IN CAPSURE Lubeck DP1, Litwin MS, Flanders SC2, Henning JM2, Carroll PR1, 1University of California, San Francisco, CA, USA; 2TAP Holdings, Deerfield, IL, USA
	PCD10	DIFFERENCES IN END-OF-LIFE MEDICAL CARE COSTS FOR PROSTATE CANCER PATIENTS: RESULTS FROM CAPSURE DATABASE Lubeck DP1, Stoddard M1, Flanders SC2, Henning JM2, 1University of California at San Francisco, Department of Urology, San Francisco, CA, USA; 2TAP Holdings Inc., Deerfield, IL, USA; Litwin MS, University of California at Los Angeles, Department of Urology, Los Angeles, CA, USA
	PCD11	COST EFFECTIVENESS OF THE THERAPY WITH IODINE 125-SEED IMPLANTATION IN PATIENTS WITH STAGE T1 AND T2 PROSTATE CARCINOMA IN COMPARISON TO TOTAL PROSTATECTOMY AND BEAM RADIATION IN 3D-TECHNIQUE Thomas J, Kremer B, Bruchhausen Y, Rychlik R, Institute of Empirical Health Economics, Burscheid, Germany
	PCD12	COST OF MANAGING MUCOSITIS AND XEROSTOMIA IN HEAD AND NECK CANCER PATIENTS UNDERGOING CHEMORADIOTHERAPY (CRT) OR RADIATION (RT) Bonomi AE1, Palmer CS2, Ajax M1, Peeples P3, Jackson SE3, 1Battelle Memorial Institute, Seattle, WA, USA; 2MEDTAP International, Bethesda, MD, USA, 3Alza Corporation, Palo Alto, CA, USA
	PCD13	PATIENT BENEFIT QUESTIONNAIRE (PBQ) FOR XEROSTOMIA: DEVELOPMENT AND VALIDATION REPORT Mackowiak JI1, Scott-Lennox J2, Lennox R2, Wasserman T3, Jackson S4, Peeples P4, 1Center for Outcomes Research, Chapel Hill, NC, USA; 2Piedmont Research Institute, Chapel Hill, NC, USA; 3Mallinckrodt Institute of Radiology, St. Louis, MO, USA; 4Alza, Palo Alto, CA, USA
ECONOMICS & OUTCOMES ISSUES OF DIABETES
	PDD1	DISEASE MANAGEMENT PATTERNS OF TYPE 2 DIABETIC PATIENTS IN AN ACADEMIC FAMILY MEDICINE CENTER Longe RL1, Taylor AT1, Wagner PJ2, Mongan PF2, 1University of Georgia, Athens, GA, USA; 2Medical College of Georgia, Augusta, GA, USA
	PDD2	PSYCHOMETRIC PROPERTIES OF THE PATIENT BENEFIT QUESTIONNAIRE (PBQ) IN A COHORT OF DIABETIC PERIPHERAL NEUROPATHY (DPN) PATIENTS Kirchdoerfer LJ1, Reiber G2, Choudhury, SR2, Sullivan, S2, 1Genentech Inc, S. San Francisco, CA, USA; 2University of Washington, Seattle WA, USA
	PDD3	A COST-OF-TREATMENT MODEL FOR TYPE 2 DIABETES Stephens JM1, Botteman MF1, Ramsdell JW2, Grossman JA3, Arocho R4, 1PAREXEL, Alexandria, VA, USA; 2University of California, San Diego, CA, USA; 3Columbia University, New York, NY, USA; 4Pfizer Inc, New York, NY, USA
	PDD4	DEVELOPMENT OF HEALTH STATE DESCRIPTIONS OF DIABETIC PERIPHERAL NEUROPATHY FOR A NEW UTILITY INSTRUMENT Lew DP, Augenstein DV, Sullivan SD, Reiber GE, University of Washington, Seattle, WA, USA
	PDD5	ONYCHOMYCOSIS AND ITS IMPACT ON SECONDARY INFECTION DEVELOPMENT IN THE DIABETIC POPULATION Boyko, WL, Doyle JJ, Ryu S, Gause DO, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
ECONOMICS & OUTCOMES ISSUES OF GASTROINTESTINAL DISORDERS
	PGI1	COSTS AND PRACTICE PATTERNS ASSOCIATED WITH TREATING GASTROESOPHAGEAL REFLUX DISEASE (GERD) IN A MANAGED CARE POPULATION Nichol MB1, Harada ASM1, Jones J1, Venturini F1, Johnson JN2, O'Connor RD3, Gilderman A4, 1University of Southern California, Los Angeles, CA, USA; 2Bay Shores Medical Group, Torrance, CA, USA; 3Sharp Rees-Stealy Medical Group, San Diego, CA, USA; 4Prescription Solutions, Costa Mesa, CA, USA
	PGI2	OMEPRAZOLE, AMOXICILLIN, AND CLARITHROMYCIN FOR H. PYLORI ERADICATION PRODUCES GREATEST COST SAVINGS IN MALAYSIAN DUODENAL ULCER PATIENTS Conway DP, Chang RJ, Cutler AF, Goh KL, Abbott Laboratories, Abbott Park, IL, USA
	PGI3	PRESCRIPTION TO OVER-THE-COUNTER PRODUCTS: HISTAMINE-2-RECEPTOR ANTAGONISTS IN THE UK Rolnick M, Furler M, Mak M, Lawday K, Einarson TR, Faculty of Pharmacy, Graduate Department of Pharmaceutical Sciences, University of Toronto, Toronto, Ontario, Canada
	PGI4	PRESCRIPTION TO OVER-THE-COUNTER PRODUCTS: HISTAMINE-2-RECEPTOR ANTAGONISTS IN THE USA Rolnick M, Furler M, Mak M, Lawday K, Einarson TR, Faculty of Pharmacy, Graduate Department of Pharmaceutical Sciences, University of Toronto, Toronto, Ontario, Canada
	PGI5	FACTORS INFLUENCING THE DURATION OF GI MEDICATION TREATMENT ASSOCIATED WITH NSAID INDUCED GASTROPATHY Wu WK1, Etzel, J1, McHugh J2; 1St. John's University College of Pharmacy, Jamaica, NY, USA; 2National Medical Health Card Systems, Inc., Port Washington, NY, USA
	PGI6	SEQUENCING OF TREATMENTS IN VARICEAL BLEEDING Zaman A1, Arnold RJG2, Pettit KG2, Kamniecki DJ2, Zacker C3, Helfand M1, 1Oregon Health Sciences University, Portland, OR, USA; 2Pharmacon International, Inc., New York, NY, USA; 3Novartis Pharmaceuticals Corp., East Hanover, NJ, USA
	PGI7	RATE OF GI DISTRESS AMONG PATIENTS TREATED WITH CELECOXIB, PLACEBO, NSAIDS USING THREE DIFFERENT STATISTICAL METHODS Zhao SZ1, Burke TA1, Maurath CJ1, Zabinski RA1, 1G.D. Searle & Co., Skokie, IL, USA
ECONOMICS & OUTCOMES ISSUES OF KIDNEY/URINARY TRACT DISORDERS
	PKU1	A METHOD FOR COMPARING DISPARATE OUTCOME MEASURES IN IN TRIALS OF URINARY INCONTINENCE OVERACTIVE BLADDER CLINICAL TRIALS Casciano R1, Arikian SA1,2, Tarride J-E2, Corey R2, Doyle J1,4, 1The Analytica Group, New York, NY, USA; 2Columbia University, New York, NY, USA; 4University of the Sciences in Philadelphia, Philadelphia, PA, USA
	PKU2	IMPROVEMENTS IN CLINICAL OUTCOMES, HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND SYMPTOM BOTHER FOR OVERACTIVE BLADDER PATIENTS TREATED WITH A NEW ONCE-DAILY FORMULATION OF OXYBUTYNIN Lubeck D1, Prebil L2, Potter L2, Peeples P3, 1Urology Dept., UCSF/Mt. Zion Cancer Center, San Francisco, CA, USA; 2Lewin-TAG, Inc., San Francisco, CA, USA; 3ALZA Corp., Palo Alto, CA, USA
	PKU3	LINGUISTIC VALIDATION OF THE URINARY INCONTINENCE QUALITY OF LIFE QUESTIONNAIRE Conway K1, Pouget C1, Marquis P2, Girod I2, McCarthy C3, 1Mapi Research Institute, Lyon, France; 2Mapi Values, Lyon, France; 3Synthélabo Recherche, Bagneux, France
	PKU4	LINGUISTIC VALIDATION OF THE KING'S HEALTH QUESTIONNAIRE (KHQ) IN 8 LANGUAGES Conway K1, Uzun V1, Marrel A2, Cardozo L3, Kelleher C4, Haye I,5, 1Mapi Research Institute, Lyon, France; 2Mapi Values, Lyon, France, 3King's College Hospital, London, UK, 4St Thomas' Hospital, London, UK, 5Pharmacia & Upjohn, St Quentin en Yvelines, France
	PKU5	ACUTE REJECTION EPISODES ARE ASSOCIATED WITH HIGHER UTILIZATION OF RESOURCES AFTER KIDNEY TRANSPLANTATION Manninen DL1, Dong FB1, Wang F2, 1Battelle, Seattle, WA, USA; 2Wyeth-Ayerst Research, Radnor, PA, USA
	PKU6	COST-EFFECTIVENESS ANALYSIS OF MYCOPHENOLATE MOFETIL TREATMENT FOR INTRACTABLE ACUTE REJECTION IN RENAL TRANSPLANTATION RECIPIENTS Sakamaki H1, Ikeda S2, Noguchi N2, Uchida K3, Ikegami N2, 1International University of Health and Welfare, Tokyo, Japan; 2Keio University School of Medicine, Tokyo, Japan; 3Nagoya Second Red Cross Hospital, Nagoya, Japan
	PKU7	COST UTILITY ANALYSIS OF LIVER AND KIDNEY TRANSPLANTATION IN GERMANY Greiner W, Schulenburg M, Centre for Health Economics and Health System Research, University of Hannover, Hannover, Germany
ECONOMICS & OUTCOMES ISSUES OF PAIN MANAGEMENT
	PCP1	A THREE-PHASED DECISION ANALYTIC MODEL FOR THE ECONOMIC EVALUATION OF OPIOID THERAPY FOR CHRONIC PAIN Neighbors DM1, Bell TJ1, Wilson J2, Dodd SL2, 1Research Triangle Institute, Research Triangle Park, NC, USA; 2Janssen Research Foundation, Titusville, NJ, USA
	PCP2	IMPACT OF PATIENT EDUCATION ON QUALITY OF LIFE IN HEADACHE TREATMENT Solomon GD1, Mannix LK2, Cleveland Clinic Foundation, Cleveland, OH, USA; Adelman Headache Center, Greensboro, NC, USA
	PCP3	THE ECONOMIC COST OF ACETAMINOPHEN-RELATED LIVER TOXICITY TO THE CALIFORNIA MEDICAID PROGRAM Menzin J, deFriesse R, O'Donoghue S, Friedman M, Boston Health Economics, Inc., Billerica, MA, USA
	PCP4	LINGUISTIC VALIDATION OF THE PATIENT PERCEPTION OF MIGRAINE QUESTIONNAIRE (PPMQ) IN 16 LANGUAGES Conway K1, Uzun V1, Black L2, 1Mapi Research Institute, Lyon, France; 2Glaxo Wellcome Inc., Research Triangle Park, NC, USA
	PCP5	USE OF OPIOID ANALGESICS FOR NON-MALIGNANT PAIN CONDITIONS: A CROSS-SECTIONAL CHARACTERIZATION Sesti AM, Dodd SL, Rai RB, Wilson J, Janssen Research Foundation, Titusville, NJ, USA
	PCP6	OPIOID ANALGESICS USE IN PATIENTS WITH NON-MALIGNANT PAIN: SELECTING AN APPROPRIATE COMPARISON GROUP Loughlin JE1, Walker AM1, Cole JA1, Wilson J2, Dodd SL2, Sesti A-M2, 1Epidemiology Resources Inc., Newton, MA, USA; 2Janssen Research Foundation, Titusville, NJ, USA
	PCP7	COSTS AND OUTCOMES OF REGIONAL VS GENERAL VS COMBINATION ANESTHESIA AND ANALGESIA TECHNIQUES IN GREEK PATIENTS UNDERGOING HIP ARTHROPLASTY Yfantopoulos Y1, Athanasiadis H2, Karokis A3, Tsekouras V3, Yourgioti G3, Pierrakos G1, Karamihali E4, Hantziandreou E5, 1University of Athens, Athens, Greece; 2Hellenic Airforce Hospital, Athens, Greece; 3Astra Hellas, Athens, Greece; 4Evangelismos Hospital, Athens, Greece, 5ASTRA A.B, Athens, Greece
	PCP7	ASSESSMENT OF SURGICAL ANAESTHESIA AND POST OPERATIVE ANALGESIA USING A PAIN VISUAL ANALOGUE SCALE Yfantopoulos Y1, Athanasiadis H2, Karokis A3, Tsekouras V3, Yourgioti G3, Pierrakos G1, Pagouni H4, Hantziandreou E5, 1University of Athens, Athens, Greece; 2Hellenic Airforce Hospital, Athens, Greece; 3Astra Hellas, 4Nikea General Hospital, Athens, Greece; 5ASTRA A.B, Athens, Greece
	PCP8	THE ANALGESIC EFFICACY AND THERAPEUTIC ONSET OF ANALGESIA OF INTRAVENOUS AND INTRAMUSCULAR KETOROLAC (15 MG AND 30 MG), AND ORAL IBUPROFEN 800 MG IN THE EMERGENCY ROOM: A COMPARATIVE STUDY Habib M1, Brofeldt B2, Supernaw B3, 1University of Texas, Austin, TX, USA; 2University of California Davis Medical Center, Davis, CA, USA; 3Texas Technological University, Amarillo, TX, USA
ECONOMICS & OUTCOMES ISSUES OF WOMEN'S AND MEN'S HEALTH DISORDERS
	PWM1	COMPARATIVE CLINICAL ECONOMICS OF THE INTRAUTERINE LEVONORGESTREL- RELEASING SYSTEM MIRENA IN WOMEN REQUIRING CONTRACEPTION Milne RJ1,2, Roberts H2, 1Health Outcomes Associates Ltd, 2University of Auckland, New Zealand
	PWM2	EFFECTIVENESS AND COST IMPACT OF EMERGENCY CONTRACEPTION OBTAINED FROM A PHARMACIST IN WASHINGTON STATE Marciante KD, Gardner JS, Sullivan SD, University of Washington, Seattle, Washington, USA
	PWM3	IMPLICATIONS OF MENOPAUSAL SYMPTOMS ON QUALITY OF LIFE Girod I1, Adesina A2, Keininger DL2, Wool C3, Marquis P1, 1Mapi Values, Lyon, France; 2Mapi Research Institute, Lyon France; 3Bracco S.p.a., Milano, Italy
	PWM4	THE RELATIONSHIP BETWEEN NOTTINGHAM HEALTH PROFILE DOMAINS AND CLINICAL CHARACTERISTICS OF WOMEN WITH ESTABLISHED POSTMENOPAUSAL OSTEOPOROSIS Foster SA1, Coons SJ2, Minshall ME1, Hays RD3, Draugalis JR2, 1Eli Lilly and Company, Indianapolis, IN, USA; 2University of Arizona, College of Pharmacy, Tucson, AZ, USA; 3University of California at Los Angeles School of Medicine, Los Angeles, CA, USA
	PWM5	COMPARISON OF QUALITY OF LIFE SCORES BETWEEN MENOPAUSAL WOMEN AND AGE-MATCHED PEERS Keininger DL1, Abetz L2, Girod I3, Adesina A1, Dubois DJ4, Wool C5, Marquis P3, 1Mapi Research Institute, Lyon France; 2Mapi Values, Cheshire, UK; 3Mapi Values, Lyon, France; 4Janssen Research Foundation, Beerse, Belgium; 5Bracco S.p.a., Milano, Italy
	PWM6	IMPACT OF POSTMENOPAUSAL HORMONE REPLACEMENT THERAPY ON RESOURCE UTILIZATION ASSOCIATED WITH ADVERSE EVENTS Chawla AJ1, Kennedy ST1, Ohsfeldt RL2, 1The MEDSTAT Group, Inc., Washington, DC, USA; 2Eli Lilly and Company, Indianapolis, IN, USA
	PWM7	COST-EFFECTIVENESS OF ESTROGEN REPLACEMENT THERAPY (ERT) ON THE PREVENTION OF OSTEOPOROSIS: SHORT TERM VERSUS LONG TERM THERAPY Liu G, Kamath T, Lee G, Chung F, Chung J, Lee S, Na J, Ngo S, Park M, Senuma K, You C, University of Southern California, Los Angeles, CA, USA
	PWM8	COST EFFECTIVENESS OF VIAGRA VS. MUSE IN THE TREATMENT OF MALE ERECTILE DYSFUNCTION Liu G, Kamath T, Cahili R, Fukui C, Goodman A, Hong J, Huang I, Lai J, Le R, Le S, Su A, Tran S, Tran T, Tsai B, University of Southern California, Los Angeles, CA, USA
	PWM9	ECONOMIC EVALUATION IN REAL-LIFE SETTING OF ALPHA-BLOCKERS VS. FINASTERIDE VS. SERENOA REPENS IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA Schmitt C1, Aussage P1, Berdeaux G2, 1ARCOS, Issy-les-Moulineaux, France; 2Pierre Fabre Médicament, Boulogne-Billancourt, France
USE OF OUTCOMES RESEARCH (ECONOMIC, CLINICAL, HUMANISTIC) IN HEALTH CARE DECISION-MAKING
	PPO1	THE ROLE OF QUALITY OF LIFE INFORMATION IN MANAGED CARE DECISION-MAKING Crawford B1, Dukes E2, Bailey L3, Evans C1, 1MAPI Values, Boston, MA, USA; 2Astra Pharmaceuticals, Chesterbrook, PA, USA; 3MAPI Values, Bollington, UK
	PPO2	THE DEVELOPMENT OF A PRACTICAL PROVIDER PROFILING REPORT Gevirtz F, Nash DB, Moxey ED, O'Connor JP, Turk B, Corrato R, Office of Health Policy and Clinical Outcomes, Philadelphia, PA, USA
	PPO3	DESIGNING A USER-FRIENDLY OUTCOMES RESEARCH DATABASE FOR THE PRIVATE MEDICAL PRACTITIONER Sarpong, DF, Xavier University College of Pharmacy, New Orleans, LA, USA
	PPO4	COMMUNITY PHARMACIST ASSESSMENT OF THE MOTIVATIONS FOR PROVIDING PHARMACEUTICAL CARE ACROSS FOUR DOMAINS Spruill WJ, Wade WE, Longe RL, Taylor TA, Burke SI, University of Georgia, Athens, GA, USA
	PPO5	PHARMACIST ASSESSMENT OF THE VALUE OF PROVIDING PHARMACEUTICAL CARE IN THE COMMUNITY PHARMACY SETTING Wade WE, Spruill WJ, Longe RL, Taylor TA, Burke SI, University of Georgia, Athens, GA, USA
	PPO6	TIME DEPENDENT SURVIVAL ANALYSIS OF A PHARMACIST'S CONSULTATION INTERVENTION STUDY Yuan Y1, Hay J2, McCombs J2, Groshen S3, Parker J2, 1Bristol-Myers Squibb, Plainsboro, NJ, USA; 2Department of Pharmaceutical Economics & Policy, and 3Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA
	PPO7	UTILIZATION OF AMBULATORY CARE SERVICES DUE TO ADVERSE EFFECTS OF MEDICATIONS IN THE UNITED STATES Aparasu RR, Helgeland DL, College of Pharmacy, South Dakota State University, Brookings, SD, USA
	PPO8	AN EMPIRICAL ANALYSIS ON AMBULATORY CARE UTILIZATION: APPLICATION OF A COUNT DATA MODEL Sengupta N, Nichol MB, Pharmaceutical Economics & Policy, University of Southern California, Los Angeles, CA, USA
	PPO9	USING OUTCOMES RESEARCH TO DEMONSTRATE QUALITY IMPROVEMENT FOR NCQA ACCREDITATION: A CASE STUDY Way K1, Young C1, Opland E2, Whitehouse D2, Hughes T1, 1PCS Health Systems, Scottsdale, AZ, USA; 2MCC Behavioral Care, Eden Prairie, MN, USA
	PPO10	UNDERSTANDING THE PROCESS AND ROLE OF TECHNOLOGY ASSESSMENT IN LARGE HEALTH MAINTENANCE ORGANIZATIONS Wise S, Foster R, Taggar N, Kirchdoerfer L, Genentech, Inc., South San Francisco, CA, USA
	PPO11	NEW METHODS OF DATA COLLECTION IN THE COMMUNITY-BASED PHYSICIAN SETTING: OVERVIEW OF THE PROCESS AND PRESENTATION OF DESCRIPTIVE STATISTICS Jardina P, Irwin C, Physicians Data Corporation, Atlanta, GA, USA
	PPO12	EFFECT OF PLAN CHARACTERISTICS ON THE COST OF PHARMACEUTICALS IN A PRIVATE THIRD-PARTY PRESCRIPTION PROGRAM Momin SR1, Lipson DP1, Marcoux RM2, 1University of Rhode Island, Kingston, RI, USA; 2MIM Health Plans,Inc., Wakefield, RI, USA
OUTCOMES (QUALITY OF LIFE) RESEARCH METHODS ISSUES
	POR1	METHODOLOGY FOR DEVELOPING AN INDEX SCORE FOR BOTHERSOMENESS OF ADVERSE EVENTS Becker LA1, Cramer JA2, Ashraf T1, 1Abbott Laboratories, Abbott Park, Il, USA; 2Yale University, New Haven, CT, USA
	POR2	PSYCHOMETRIC EVALUATION OF THE PATIENT MEDICATION ADHERENCE QUESTIONNAIRE Jordan J, Tolson J, Jhingran P, Demasi R, Pham S, Capuano G, Glaxo Wellcome Inc, Research Triangle Park, NC, USA
	POR3	EDMONTON QUALITY ASSESSMENT TOOL FOR DRUG UTILIZATION REVIEWS (EQATDUR): AN INSTRUMENT FOR ASSESSING THE METHODOLOGIC RIGOR OF DRUG UTILIZATION REVIEWS Spooner CH, Pickard AS, Menon D, Assiff L, Institute of Pharmaco-Economics, Edmonton, AB, Canada
	POR4	LINGUISTIC VALIDATION OF THE SLICE/LIFE QUESTIONNAIRE Conway K1, Pouget C1, Keller MB2, Walker C2, Leventhal N2, Revicki D3, Namjoshi M4, Tohen M4,5, 1Mapi Research Institute, Lyon, France; 2Brown University, Providence, RI, USA; 3Medtap International, Bethesda, MD, USA; 4Eli Lilly and Company, Indianapolis, IN, USA; 5Harvard Medical School, Boston, MA, USA
	POR5	EVALUATION OF THE ANALYTICAL HIERARCHY PROCESS (AHP) AS A TOOL IN FORMULARY DEVELOPMENT Wilson, AE1, Grandzol JR2, 1PennState Geisinger Health System, Danville, PA, USA; 2Wilkes University, Wilkes-Barre, PA, USA
	POR6	EVALUATION OF THE STRUCTURAL VALIDitY OF THE SF-12 Reed, PJ1, Moore DD2, 1University of Tennessee-Memphis, Memphis, TN, USA; 2Clemson University, Clemson, SC, USA
	POR7	DEVELOPING A QUALITY ASSESSMENT SCORING SYSTEM FOR ECONOMIC EVALUATIONS TC "DEVELOPING A QUALITY ASSESSMENT SCORING SYSTEM FOR ECONOMIC EVALUATIONS" Pang F1, Tolley K2, 1Centre for Health Economics, University of York, York, UK; 2Outcomes Research, Central Research, Pfizer Ltd., Sandwich, UK
	POR8	MINIMAL STANDARDS FOR THE VALIDATION OF QUALITY OF LIFE INSTRUMENTS USED IN CLINICAL TRIALS Chassany O1, Fullerton S2,3, Wiklund I2, Apolone G4, Aquadro C5, Jambon B5, for the European Regulatory Issues on QoL Assessment (ERIQA) group, 1Hopital Lariboisiere, Paris, France; 2Astra Hassle, Molndal, Sweden; 3UCLA Department of Medicine, Los Angeles, CA, USA; 4Mario Negri Institute, Milan, Italy; 5MAPI Research Institute, Lyon, France
	POR9	CLINICAL EPIDEMIOLOGY PRINCIPLES OF AND THE COST OF DRUG TRIALS Gorkov V, Kobina S, Churilin Y, Sc. Center of Mental Health, Moscow, Russia
	POR10	PREDICTING MARKET SHARES FOR NEW PHARMACEUTICAL PRODUCTS USING STATED PREFERENCES Bingham MF1, Johnson FR1, 1Triangle Economic Research, Durham, NC, USA
PHARMACOECEONOMIC RESEARCH METHODS ISSUES
	PPR1	PRE-TEST OF A MARKOV MODEL TO ESTIMATE THE COST OF ILLNESS IN AMBULATORY PATIENTS: A PRELIMINARY ESTIMATE USING PHYSICIAN SURVEY DATA Halberg DL, University of Arkansas for Medical Sciences, Little Rock, AR, USA
	PPR2	EVALUATION OF AN EDUCATIONAL INTERVENTION ON THE PERCEPTION OF COST-EFFECTIVE INFORMATION RELATIVE TO CLINICAL INFORMATION Sarratt D, Cox ER, University of Arizona, College of Pharmacy, Tucson, AZ, USA
	PPR3	THE ROLE OF PHARMACOECONOMIC INVESTIGATIONS IN CREATING THE PATIENT'S TREATMENT RECORD Vorobjev PA, Kobina SA, Vyalkov AI, Semenov VYu, Yakimov OS, Novolodskii VM, Belousov YuB, Moscow Medical Academy, Moscow, Russia
	PPR4	DEVELOPING METHODOLOGICAL STANDARDS IN PHARMACOECONOMIC RESEARCH: AN APPROACH BY A TASK FORCE OF THE AMERICAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY Hirschfeld, RMA1, Russell, J1, Hylan, TR2, 1University of Texas Medical Branch, Galveston, TX, USA; 2Eli Lilly and Company, Indianapolis, IN, USA for the ACNP Task Force on Development of Methodological Standards in Pharmacoeconomic Research
	PPR5	ESTIMATING HEALTH-CARE COSTS IN THE ABSENCE OF FINANCIAL DATA: A CASE STUDY Russell, MW, Huse, DM, Miller, JD, Hartz, SC, Medical Research International, Burlington, MA, USA
	PPR6	COST-EFFECTIVENESS ANALYSIS: A SIMULTANEOUS MARGINAL-EFFECT APPROACH Liu G, University of Southern California, Los Angeles, CA, USA; Zhao Z, Merck-Medco Managed Care, Montvale, NJ, USA
	PPR7	A FORMAL AUDIT OF 228 PUBLISHED COST-UTILITY ANALYSES Neumann P, Stone P, Chapman R, Sandberg E, Harvard School of Public Health, Boston, MA, USA
USE OF PHARMACOECONOMICS - COUNTRY-SPECIFIC ISSUES
	PUP1	PHARMACOECONOMICS IN RUSSIA: FIRST STEPS Moisseyev S, Moscow Medical Academy, Moscow, Russia
	PUP2	PHARMACOECONOMIC INFORMATION IN FORMULARY DECISION MAKING IN THE UNITED STATES Evans C1, Dukes E2, Bailey L3, Crawford B1, 1MAPI Values, Boston, MA, USA ; 2Astra Pharmaceuticals, Chesterbrook, PA, USA; 3MAPI Values, Bollington, UK
	PUP3	ANALYSIS OF THE ECONOMIC IMPACT OF AN INCREASE IN THE UTILIZATION OF GENERIC MEDICATIONS IN PORTUGAL Vilas-Boas IM, Assoçião Nacional das Farmâcias, Lisbon, Portugal
	PUP4	IMPLEMENTATION OF PHARMACOECONOMIC ANALYSIS IN NORWAY, ARE THE USERS PREPARED? Rorvik EM, Toverud E-L, School of Pharmacy, University of Oslo, Oslo, Norway
	PUP5	ECONOMIC IMPACT OF PRESCRIBING IN THE URBAN COMMUNITY OF DELHI Bapna JS1, Sapir DG2, Roy P3, 1Institute of Human Behavior & Allied Sciences, Delhi, India; 2Council for Social Development, Delhi, India; 3University of Luvain, Brussels, Belgium

Annual International Meeting Main Page